Issue 1, 2021

The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct

Abstract

Arsenoplatin-1 (AP-1) is an innovative dual-action anticancer agent that contains a platinum(II) center coordinated to an arsenous acid moiety. We found that AP-1 spontaneously aggregates in aqueous solutions generating oligomeric species of increasing length. Afterward, we succeeded in solving the crystal structure of the adduct formed between the model protein lysozyme and an early AP-1 oligomer that turned out to be a trimer. Remarkably, this crystal structure traps an early stage of AP-1 aggregation offering detailed insight into the molecular process of the oligomer's growth.

Graphical abstract: The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct

Supplementary files

Article information

Article type
Communication
Submitted
07 Oct 2020
Accepted
27 Nov 2020
First published
27 Nov 2020

Dalton Trans., 2021,50, 68-71

The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct

G. Ferraro, D. Cirri, T. Marzo, A. Pratesi, L. Messori and A. Merlino, Dalton Trans., 2021, 50, 68 DOI: 10.1039/D0DT04068A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements